Search
Close this search box.

HIV Management Guidelines

HIV Management Guidelines

Search
Close this search box.

HIV-infectious Disease & Cancer

Management > HIV-infectious Disease & Cancer > References

Sections

Sections

References

  1. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nature reviews Disease primers. 2015;1(1):1-22.
  2. Hogan MT. Cutaneous infections associated with HIV/AIDS. Dermatologic clinics. 2006;24(4):473-95.
  3. Veenstra J, Krol A, van Praag RME, Frissen PMJ, Schellekens PTA, Lange JMA, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. Aids. 1995;9(10):1153-8.
  4. Strick LB, Wald A, Celum C. Management of Herpes Simplex Virus Type 2 Infection in HIV Type 1–Infected Persons. Clinical Infectious Diseases. 2006;43(3):347-56. doi: 10.1086/505496.
  5. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current ART era. Journal of acquired immune deficiency syndromes (1999). 2012;61(2):203.
  6. Looker KJ, Magaret AS, May MT, Turner KME, Vickerman P, Gottlieb SL, et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PloS one. 2015;10(10):e0140765.
  7. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bulletin of the World Health Organization. 2008;86(10):805-12A.
  8. Whitley RJ, Roizman B. Herpes simplex virus infections. The lancet. 2001;357(9267):1513-8.
  9. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. New England Journal of Medicine. 2008;358(15):1560-71.
  10. Van de Perre P, Segondy M, Foulongne V, Ouedraogo A, Konate I, Huraux J-M, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. The Lancet infectious diseases. 2008;8(8):490-7.
  11. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids. 2006;20(1):73-83.
  12. V Barnabas R, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Current HIV research. 2012;10(3):228-37.
  13. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. Journal of the American Academy of Dermatology. 2007;57(5):737-63; quiz 64-6. Epub 2007/10/18. doi: 10.1016/j.jaad.2007.06.027. PubMed PMID: 17939933.
  14. Carrasco DA, Trizna Z, Colome-Grimmer M, Tyring SK. Verrucous herpes of the scrotum in a human immunodeficiency virus-positive man: case report and review of the literature. Journal of the European Academy of Dermatology and Venereology : JEADV. 2002;16(5):511-5. Epub 2002/11/14. doi: 10.1046/j.1468-3083.2002.00500.x. PubMed PMID: 12428850.
  15. Brodt RH, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. Aids. 1997;11(14):1731-8.
  16. Schwartländer B, Horsburgh CR, Jr., Hamouda O, Skarabis H, Koch MA. Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991. Aids. 1992;6(4):413-20. Epub 1992/04/11. doi: 10.1097/00002030-199204000-00009. PubMed PMID: 1352106.
  17. Looker KJ, Johnston C, Welton NJ, James C, Vickerman P, Turner KME, et al. The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study. BMJ global health. 2020;5(3):e001875.
  18. Ryan C, Kinghorn G. Clinical assessment of assays for diagnosis of herpes simplex infection. Expert review of molecular diagnostics. 2006;6(5):767-75.
  19. Kotton BD, Kotton CN. Resistant herpes simplex virus infections–who, when, and what’s new? Current Opinion in Infectious Diseases. 2022;35(6):530-5.
  20. Ashley R. Sorting out the new HSV type specific antibody tests. Sexually transmitted infections. 2001;77(4):232.
  21. Opportunistic and co-infections in adults with HIV infection. Australian Therapeutic Guidelines. Published April 2019 (Amended June 2023). Accessed via https://tgldcdp.tg.org.au.acs.hcn.com.au/ on 20th of January 2024.
  22. Jiang Y-C, Feng H, Lin Y-C, Guo X-R. New strategies against drug resistance to herpes simplex virus. International journal of oral science. 2016;8(1):1-6.
  23. Patel R, Bodsworth NJ, Woolley P, Peters B, Vejlsgaard G, Saari S, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourinary medicine. 1997;73(2):105.
  24. World Health O. WHO guidelines for the treatment of genital herpes simplex virus: World Health Organization; 2016.
  25. Patel R, Kennedy OJ, Clarke E, Geretti A, Nilsen A, Lautenschlager S, et al. 2017 European guidelines for the management of genital herpes. International journal of STD & AIDS. 2017;28(14):1366-79.
  26. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. Aids. 1997;11(14):1731-8. Epub 1997/12/05. doi: 10.1097/00002030-199714000-00010. PubMed PMID: 9386808.
  27. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. Nature reviews Disease primers. 2015;1(1):1-18.
  28. Gershon AA, Mervish N, LaRussa P, Steinberg S, Lo SH, Hodes D, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. Journal of Infectious Diseases. 1997;176(6):1496-500.
  29. Ku HC, Tsai YT, Konara-Mudiyanselage SP, Wu YL, Yu T, Ko NY. Incidence of Herpes Zoster in HIV-Infected Patients Undergoing Antiretroviral Therapy: A Systematic Review and Meta-analysis. Journal of clinical medicine. 2021;10(11). Epub 2021/06/03. doi: 10.3390/jcm10112300. PubMed PMID: 34070645; PubMed Central PMCID: PMC8198877.
  30. McCrary ML, Severson J, Tyring SK. Varicella zoster virus. Journal of the American Academy of Dermatology. 1999;41(1):1-16.
  31. Cohen PR, Beltrani VP, Grossman ME. Disseminated herpes zoster in patients with human immunodeficiency virus infection. The American journal of medicine. 1988;84(6):1076-80.
  32. Agarwal N, Mittal A, Kuldeep CM, Gupta LK, Khare AK, Mehta S. Chemical reconstruction of skin scars therapy using 100% trichloroacetic acid in the treatment of atrophic facial post varicella scars: a pilot study. Journal of cutaneous and aesthetic surgery. 2013;6(3):144.
  33. Sampathkumar P, Drage LA, Martin DP, editors. Herpes zoster (shingles) and postherpetic neuralgia2009: Elsevier.
  34. Johnson RW, Rice ASC. Postherpetic neuralgia. New England Journal of Medicine. 2014;371(16):1526-33.
  35. Dollard S, Chen M-h, Lindstrom S, Marin M, Rota PA. Diagnostic and immunologic testing for varicella in the era of high-impact varicella vaccination: an evolving problem. The Journal of Infectious Diseases. 2022;226(Supplement_4):S450-S5.
  36. Yeh C-H, Chang K-S, Huang S-S, Tsay S-L, Tsai J-M, Wang Y-J, editors. Comparing prodrugs with acyclovir for treating postherpetic neuralgia among herpes zoster patients: a systematic review and meta-analysis2022: MDPI.
  37. Immunocompetent Patients With Complications of Chickenpox and Immunocompromised Patients With Chickenpox. Australian Therapeutic Guidelines. Published April 2019. Accessed via https://tgldcdp.tg.org.au.acs.hcn.com.au/ on 20th of January 2024.
  38. Breton G, Fillet A-M, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clinical infectious diseases. 1998;27(6):1525-7.
  39. Son M, Shapiro ED, LaRussa P, Neu N, Michalik DE, Meglin M, et al. Effectiveness of varicella vaccine in children infected with HIV. The Journal of infectious diseases. 2010;201(12):1806-10.
  40. Levin MJ, Gershon AA, Weinberg A, Song L-Y, Fentin T, Pediatric ACTGT. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. The Journal of infectious diseases. 2006;194(2):247-55.
  41. Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Human vaccines. 2010;6(4):318-21. Epub 2010/04/08. doi: 10.4161/hv.6.4.10654. PubMed PMID: 20372089.
  42. Australian Government Department of Health and Aged Care. Australian Immunisations Handbook – Vaccination for People Who Are Immunocompromised. 13 December 2023. Accessed via https://immunisationhandbook.health.gov.au/ on 20 January 2024.
  43. Australian Government Department of Health and Aged Care. National Immunisation Program – Shingles Program Advice for Vaccination Providers. 08 October 2023 (Updated 10 November 2023). Accessed via https://www.health.gov.au/resources/publications/national-immunisation-program-shingles-program-advice-for-vaccination-providers on 01 March 2024.
  44. Australian Government Department of Health and Aged Care. Australian Immunisations Handbook – Zoster Immunoglobulin-VF (human). 07 June 2018. Accessed via https://immunisationhandbook.health.gov.au/immunoglobulins/zoster-immunoglobulin-vf-human on 20 January 2024.
  45. Albrecht MA, Levin MJ, Edwards MS, Blake D. Post-exposure prophylaxis against varicella-zoster virus infection. Up To Date Jan. 2021.
  46. Barnabas RV, Baeten JM, Lingappa JR, Thomas KK, Hughes JP, Mugo NR, et al. Acyclovir prophylaxis reduces the incidence of herpes zoster among HIV-infected individuals: results of a randomized clinical trial. The Journal of infectious diseases. 2016;213(4):551-5.
  47. Syrjänen S, Leimola‐Virtanen R, Schmidt‐Westhausen A, Reichart PA. Oral ulcers in AIDS patients frequently associated with cytomegalovirus (CMV) and Epstein‐Barr virus (EBV) infections. Journal of oral pathology & medicine. 1999;28(5):204-9.
  48. Farisyi MA, Sufiawati Detection of Epstein–Barr virus DNA in saliva of HIV-1-infected individuals with oral hairy leukoplakia. Oral Diseases. 2020;26(S1):158-60. doi: https://doi.org/10.1111/odi.13400.
  49. MacPhail AI, McLean C, Vujovic O, Hoy JF. A 44-year-old man with an ulcerating skin rash in the setting of advanced human immunodeficiency virus infection. Aids. 2021;35(8):1325-6.
  50. Australian Therapeutic Guidelines. Cytomegalovirus (CMV) Infection. April 2019. Accessed via https://www.tg.org.au/ on 20 January 2024. .
  51. Muñoz N, Castellsagué X, de González AB, Gissmann HPV in the etiology of human cancer. Vaccine. 2006;24:S1-S10.
  52. Roberts JM, Poynten IM, Molano M, Machalek DA, Hillman RJ, Guzman P, et al. Human papillomavirus genotypes in anal high-grade squamous intraepithelial lesion (HSIL): anal intraepithelial neoplasia grades 2 (AIN2) and 3 (AIN3) are different. Cancer Epidemiology, Biomarkers & Prevention. 2020;29(10):2078-83.
  53. Dall’Oglio F, D’Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: an evidence-based review. American journal of clinical dermatology. 2012;13:73-96.
  54. Chelidze K, Thomas C, Chang AY, Freeman EE. HIV-related skin disease in the era of antiretroviral therapy: recognition and management. American journal of clinical dermatology. 2019;20:423-42.
  55. Lynde C, Vender R, Bourcier M, Bhatia N. Clinical features of external genital warts. Journal of Cutaneous Medicine and Surgery. 2013;17(6_suppl):S55-S60.
  56. Schwartz RA, Janniger Bowenoid papulosis. Journal of the American Academy of Dermatology. 1991;24(2):261-4.
  57. Yoneta A, Yamashita T, Jin HY, Iwasawa A, Kondo S, Jimbow Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from bowenoid papulosis. The British journal of dermatology. 2000;143(3):604-8. Epub 2000/09/06. doi: 10.1111/j.1365-2133.2000.03718.x. PubMed PMID: 10971337.
  58. Albuquerque A, Stockdale CK, Heller D, Bornstein J, Roberts JM, Preti M, et al. Vulvar High-Grade Squamous Intraepithelial Lesions and Cancer as a Risk Factor for Anal Cancer: A Review. Journal of Lower Genital Tract Disease. 2022;26(1).
  59. Black A, Saccomanno R, Stowers JM, Markinson BC. Verrucous Lesions: When To Biopsy, When Not to Biopsy. Podiatry Today. 2017;30(10).
  60. Clarke MA, Wentzensen Strategies for screening and early detection of anal cancers: a narrative and systematic review and meta‐analysis of cytology, HPV testing, and other biomarkers. Cancer cytopathology. 2018;126(7):447-60.
  61. Yang J, Nolte FS, Chajewski OS, Lindsey KG, Houser PM, Pellicier J, et al. Cytology and high risk HPV testing in cervical cancer screening program: Outcome of 3‐year follow‐up in an academic institute. Diagnostic cytopathology. 2018;46(1):22-7.
  62. Nofal A, Marei A, Al-shimaa MI, Nofal E, Nabil M. Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts. Journal of the American Academy of Dermatology. 2020;82(1):94-100.
  63. Gilson RJC, Shupack JL, Friedman-Kien AE, Conant MA, Weber JN, Nayagam AT, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Aids. 1999;13(17):2397-404.
  64. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. Journal of the European Academy of Dermatology and Venereology. 2000;14(6):484-8.
  65. Descamps V, Duval X, Grossin M, Crickx B, Leport C. Topical cidofovir for bowenoid papulosis in an HIV‐infected patient. British Journal of Dermatology. 2001;144(3):642-3.
  66. Palefsky JM, Giuliano AR, Goldstone S, Moreira Jr ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New England Journal of Medicine. 2011;365(17):1576-85.
  67. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. New England Journal of Medicine. 2020;383(14):1340-8.
  68. Zizza A, Banchelli F, Guido M, Marotta C, Di Gennaro F, Mazzucco W, et al. Efficacy and safety of human papillomavirus vaccination in HIV-infected patients: a systematic review and meta-analysis. Scientific Reports. 2021;11(1):4954. doi: 10.1038/s41598-021-83727-7.
  69. Gur I. The epidemiology of Molluscum contagiosum in HIV-seropositive patients: a unique entity or insignificant finding? International Journal of STD & AIDS. 2008;19(8):503-6. doi: 10.1258/ijsa.2008.008186.
  70. van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van Suijlekom‐Smit LWA, Koning S. Interventions for cutaneous molluscum contagiosum. Cochrane Database of Systematic Reviews. 2017(5).
  71. Smith KJ, Yeager J, Skelton H. Molluscum contagiosum: its clinical, histopathologic, and immunohistochemical spectrum. Int J Dermatol. 1999;38(9):664-72. Epub 1999/10/12. doi: 10.1046/j.1365-4362.1999.x. PubMed PMID: 10517682.
  72. Yamashita H, Uemura T, Kawashima M. Molecular epidemiologic analysis of Japanese patients with molluscum contagiosum. Int J Dermatol. 1996;35(2):99-105. Epub 1996/02/01. doi: 10.1111/j.1365-1996.tb03270.x. PubMed PMID: 8850036.
  73. Sen S, Bhaumik P. Resolution of giant Molluscum contagiosum with antiretroviral therapy. Indian Journal of Dermatology, Venereology and Leprology. 2008;74:267.
  74. Ibarra V, Blanco JR, Oteo JA, Rosel L. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Dermato-Venereologica. 2000;80(4):315-6.
  75. Toro JR, Wood LV, Patel NK, Turner ML. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Archives of Dermatology. 2000;136(8):983-5.
  76. Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe J-J, Marks M, et al. Monkeypox. The Lancet. 2023;401(10370):60-74.
  77. Ortiz-Saavedra B, Montes-Madariaga ES, Cabanillas-Ramirez C, Alva N, Ricardo-Martínez A, León-Figueroa DA, et al. Epidemiologic Situation of HIV and Monkeypox Coinfection: A Systematic Review. Vaccines [Internet]. 2023; 11(2).
  78. Australian Government Department of Health and Aged Care. National Notifiable Disease Surveillance System. Updated 17 Jan 2024. Accessed via https://nindss.health.gov.au/pbi-dashboard/ on 20 January 2024.
  79. Frew JW. Monkeypox: Cutaneous clues to clinical diagnosis. Journal of the American Academy of Dermatology. 2023;88(3):698-700.
  80. Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet (London, England). 2022;400(10353):661-9. Epub 2022/08/12. doi: 10.1016/s0140-6736(22)01436-2. PubMed PMID: 35952705; PubMed Central PMCID: PMC9533900.
  81. Hoffmann C, Jessen H, Wyen C, Grunwald S, Noe S, Teichmann J, et al. Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany. HIV Medicine. 2023;24(4):389-97. doi: https://doi.org/10.1111/hiv.13378.
  82. Miller MJ, Cash-Goldwasser S, Marx GE, Schrodt CA, Kimball A, Padgett K, et al. Severe Monkeypox in Hospitalized Patients – United States, August 10-October 10, 2022. MMWR Morbidity and mortality weekly report. 2022;71(44):1412-7. 
  83. The Australian Government Department of Health. Australian STI Management Guidelines. Monkeypox (Mpox). Available via https://sti.guidelines.org.au/sexually-transmissible-infections/monkeypox/ on 20 January 2024. 
  84. Australian Government Department of Health and Aged Care. Monkeypox Treatment Guidelines. 24 June 2022. Accessed via https://www.health.gov.au/resources/publications/monkeypox-treatment-guidelines on 20 Jan 2024. .
  85. Australian Government Department of Health and Aged Care. Mpox (Monkeypox) Vaccines. 02 September 2022. Accessed via https://www.health.gov.au/diseases/mpox-monkeypox/vaccines on 20 January 2024. .
  86. Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, et al. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study. eClinicalMedicine. 2024;68. doi: 10.1016/j.eclinm.2023.102420.
  87. Martín-Iguacel R, Pericas C, Bruguera A, Rosell G, Martínez E, Díaz Y, et al. Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study. Microorganisms [Internet]. 2023; 11(11).
  88. Rodwell GEJ, Bayles CL, Towersey L, Aly R. The prevalence of dermatophyte infection in patients infected with human immunodeficiency virus. International Journal of Dermatology. 2008;47(4):339-43. doi: https://doi.org/10.1111/j.1365-4632.2008.03416.x.
  89. Costa JEF, Neves RP, Delgado MM, Lima-Neto RG, Morais VMS, Coêlho Dermatophytosis in patients with human immunodeficiency virus infection: clinical aspects and etiologic agents. Acta tropica. 2015;150:111-5.
  90. John AM, Schwartz RA, Janniger The kerion: an angry tinea capitis. International Journal of Dermatology. 2018;57(1):3-9. doi: https://doi.org/10.1111/ijd.13423.
  91. May PJ, Tong SYC, Steer AC, Currie BJ, Andrews RM, Carapetis JR, et al. Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review. Tropical Medicine & International Health. 2019;24(3):280-93.
  92. Millsop JW, Fazel N. Oral candidiasis. Clinics in dermatology. 2016;34(4):487-94.
  93. Taudorf EH, Jemec GBE, Hay RJ, Saunte DML. Cutaneous candidiasis–an evidence‐based review of topical and systemic treatments to inform clinical practice. Journal of the European Academy of Dermatology and Venereology. 2019;33(10):1863-73.
  94. Sobel JD. Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. International Journal of STD & AIDS. 2002;13(6):358-62. doi: 10.1258/095646202760029741.
  95. Krzyściak P, Bakuła Z, Gniadek A, Garlicki A, Tarnowski M, Wichowski M, et al. Prevalence of Malassezia species on the skin of HIV-seropositive patients. Scientific Reports. 2020;10(1):17779. doi: 10.1038/s41598-020-74133-6.
  96. Warkentien T, Crum-Cianflone NF. An update on Cryptococcus among HIV-infected patients. International journal of STD & AIDS. 2010;21(10):679-84.
  97. Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA. Scabies: a ubiquitous neglected skin disease. The Lancet infectious diseases. 2006;6(12):769-79.
  98. Johnston G, Sladden M. Scabies: diagnosis and treatment. Bmj. 2005;331(7517):619-22.
  99. Portu J, Santamaria JM, Zubero Z, Almeida-Llamas MV, San Sebastian MA-E, Gutiérrez AR. Atypical scabies in HIV-positive patients. Journal of the American Academy of Dermatology. 1996;34(5):915-7.
  100. Park JH, Kim CW, Kim SS. The diagnostic accuracy of dermoscopy for scabies. Annals of dermatology. 2012;24(2):194-9.
  101. Strong M, Johnstone P. Cochrane Review: Interventions for treating scabies. Evidence‐Based Child Health: A Cochrane Review Journal. 2011;6(6):1790-862.
  102. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. Journal of infection. 2005;50(5):375-81.
  103. Usha V, Nair TVG. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. Journal of the American Academy of Dermatology. 2000;42(2):236-40.
  104. Dunic I, Vesic S, Jevtovic Oral candidiasis and seborrheic dermatitis in HIV‐infected patients on highly active antiretroviral therapy. HIV medicine. 2004;5(1):50-4.
  105. Moreno-Coutiño G, Sánchez-Cárdenas CD, Bello-Hernández Y, Fernández-Martínez R, Arroyo-Escalante S, Arenas R. Isolation of Malassezia spp. in HIV-positive patients with and without seborrheic dermatitis. Anais Brasileiros de Dermatologia. 2019;94:527-31.
  106. Forrestel AK, Kovarik CL, Mosam A, Gupta D, Maurer TA, Micheletti RG. Diffuse HIV-associated seborrheic dermatitis–a case series. International journal of STD & AIDS. 2016;27(14):1342-5.
  107. Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review. Journal of Dermatological Treatment. 2019;30(2):158-69.
  108. Mischo M, von Kobyletzki LB, Bründermann E, Schmidt DA, Potthoff A, Brockmeyer NH, et al. Similar appearance, different mechanisms: xerosis in HIV, atopic dermatitis and ageing. Experimental dermatology. 2014;23(6):446-8.
  109. Sadick NS, McNutt NS, Kaplan MH. Papulosquamous dermatoses of AIDS. Journal of the American Academy of Dermatology. 1990;22(6):1270-7.
  110. Nosewicz J, Spaccarelli N, Roberts KM, Hart PA, Kaffenberger JA, Trinidad JC, et al. The epidemiology, impact, and diagnosis of micronutrient nutritional dermatoses part 1: Zinc, selenium, copper, vitamin A, and vitamin C. Journal of the American Academy of Dermatology. 2022;86(2):267-78.
  111. Ceccarelli M, Venanzi Rullo E, Vaccaro M, Facciolà A, d’Aleo F, Paolucci IA, et al. HIV‐associated psoriasis: epidemiology, pathogenesis, and management. Dermatologic Therapy. 2019;32(2):e
  112. Yen Y-F, Jen IA, Chen M, Lan Y-C, Lee C-Y, Chuang P-H, et al. HIV infection increases the risk of incident psoriasis: a nationwide population-based cohort study in Taiwan. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;75(5):493-9.
  113. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. 2019;80(4):1073-113. doi: https://doi.org/10.1016/j.jaad.2018.11.058.
  114. Elias M, Patel S, Schwartz RA, Lambert WC. The color of skin: red diseases of the skin, nails, and mucosa. Clinics in dermatology. 2019;37(5):548-60.
  115. Schons KRR, Beber AAC, Beck MdO, Monticielo Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. Anais brasileiros de dermatologia. 2015;90:314-9.
  116. Obuch ML, Maurer TA, Becker B, Berger TG. Psoriasis and human immunodeficiency virus infection. Journal of the American Academy of Dermatology. 1992;27(5, Part 1):667-73. doi: https://doi.org/10.1016/0190-9622(92)70234-7.
  117. Kimmel GW, Lebwohl M. Psoriasis: Overview and Diagnosis. In: Bhutani T, Liao W, Nakamura M, editors. Evidence-Based Psoriasis: Diagnosis and Treatment. Cham: Springer International Publishing; 2018. p. 1-16.
  118. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. Journal of the American Academy of Dermatology. 2017;77(4):657-e8. 
  119. Duvic M, Crane MM, Conant M, Mahoney SE, Reveille JD, Lehrman SN. Zidovudine improves psoriasis in human immunodeficiency virus—positive males. Archives of dermatology. 1994;130(4):447-51.
  120. Fischer T, Schwörer H, Vente C, Reich K, Ramadori Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. AIDS. 1999;13(5):628.
  121. Feldman SR, Koo JYM, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. Journal of the American Academy of Dermatology. 2005;53(1):101-7. 
  122. Menon K, Van Voorhees AS, Bebo Jr BF, Gladman DD, Hsu S, Kalb RE, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2010;62(2):291-9.
  123. Fotiades J, Urn HW, Jiang SB, Soter NA, Sanchez M, Moy J. Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus. Photodermatology, Photoimmunology & Photomedicine. 1995;11(3):107-11.
  124. Ranki A, Puska P, Mattinen S, Lagerstedt A, Krohn K. Effect of PUVA on immunologic and virologic findings in HIV-infected patients. Journal of the American Academy of Dermatology. 1991;24(3):404-10.
  125. Zarbafian M, Cote B, Richer V. Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report. SAGE Open Medical Case Reports. 2019;7:2050313
  126. Manfreda V, Esposito M, Campione E, Bianchi L, Giunta A. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgraduate Medicine. 2019;131(3):239-40.
  127. Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA dermatology. 2020;156(3):258-69.
  128. Services Australia, Pharmaceutical Benefits Scheme. Severe chronic plaque psoriasis – initial authority application form (PB112). 01 October 2023. Accessed from https://www.servicesaustralia.gov.au/pb112 on 24 January 2024. .
  129. Xu J, Gill K, Flora A, Kozera E, Frew JW. The impact of psoriasis biologic therapy on HIV viral load and CD4+ cell counts in HIV‐positive individuals: A real‐world cohort study. Journal of the European Academy of Dermatology and Venereology. 2023.
  130. Wang D, Chong VC-L, Chong W-S, Oon HH. A Review on Pityriasis Rubra Pilaris. American Journal of Clinical Dermatology. 2018;19(3):377-90. doi: 10.1007/s40257-017-0338-1.
  131. Miralles ES, Nunez M, De Las Heras ME, Pérez B, Moreno R, Ledo A. Pityriasis rubra pilaris and human immunodeficiency virus infection. British Journal of Dermatology. 1995;133(6):990-3.
  132. Ji-Xu A, Lei DK, Maloney NJ, Worswick S. Clinical course, diagnostic patterns, and treatment outcomes in patients with pityriasis rubra pilaris. Journal of the American Academy of Dermatology. 2022;87(6):1450-1. 
  133. González-López A, Velasco E, Pozo T, Del Villar A. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. British Journal of Dermatology. 1999;140(5):931-4. 
  134. Martin AG, Weaver CC, Cockerell CJ, Berger TG. Pityriasis rubra pilaris in the setting of HIV infection: clinical behaviour and association with explosive cystic acne. The British journal of dermatology. 1992;126(6):617-20. Epub 1992/06/01. doi: 10.1111/j.1365-1992.tb00111.x. PubMed PMID: 1535216.
  135. Basarab T, Jones RR. HIV‐associated eosinophilic folliculitis: case report and review of the literature. British Journal of Dermatology. 1996;134(3):499-503.
  136. Afonso JPJM, Tomimori J, Michalany NS, Nonogaki S, Porro AM. Pruritic papular eruption and eosinophilic folliculitis associated with human immunodeficiency virus (HIV) infection: A histopathological and immunohistochemical comparative study. Journal of the American Academy of Dermatology. 2012;67(2):269-75. 
  137. Bobotsis R, Brathwaite S, Eshtiaghi P, Rodriguez-Bolanos F, Doiron P. HIV-Inflammatory Dermatoses. Clinics in Dermatology. 2023.
  138. Boonchai W, Md RL, Manonukul J, Kulthanan Pruritic papular eruption in HIV seropositive patients: a cutaneous marker for immunosuppression. International Journal of Dermatology. 1999;38(5):348-50. 
  139. Parker SRS, Parker DC, McCall CO. Eosinophilic Folliculitis in HIV-Infected Women. American Journal of Clinical Dermatology. 2006;7(3):193-200. doi: 10.2165/00128071-200607030-00006.
  140. Rajendran PM, Dolev JC, Heaphy MR, Maurer T. Eosinophilic folliculitis: before and after the introduction of antiretroviral therapy. Archives of dermatology. 2005;141(10):1227-31.
  141. Resneck JS, Jr., Van Beek M, Furmanski L, Oyugi J, LeBoit PE, Katabira E, et al. Etiology of pruritic papular eruption with HIV infection in Uganda. Jama. 2004;292(21):2614-21. Epub 2004/12/02. doi: 10.1001/jama.292.21.2614. PubMed PMID: 15572719.
  142. WHO Guidelines Approved by the Guidelines Review Committee.  Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. Geneva: World Health Organization; 2014. .
  143. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. Journal of the American Academy of Dermatology. 2013;68(5):693-e1.
  144. Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Current opinion in immunology. 2013;25(1):81-9. Epub 2012/11/13. doi: 10.1016/j.coi.2012.10.002. PubMed PMID: 23141566.
  145. Sun HY, Gu Y, Sebaratnam Avoiding severe drug hypersensitivity reactions: a case for HLA genotyping for at-risk patients. Medical Journal of Australia. 2023;219(6):285-. 
  146. Thomas M, Hopkins C, Duffy E, Lee D, Loulergue P, Ripamonti D, et al. Association of the HLA-B* 53: 01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. Clinical Infectious Diseases. 2017;64(9):1198-203.
  147. Kardaun SH, Sekula P, Valeyrie‐Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR British Journal of dermatology. 2013;169(5):1071-80.
  148. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. Journal of the American Academy of Dermatology. 2013;68(5):709-e1.
  149. Knight L, Muloiwa R, Dlamini S, Lehloenya Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis. PLoS One. 2014;9(4):e93543.
  150. Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. American journal of clinical dermatology. 2012;13:49-54.
  151. Fagot J-P, Mockenhaupt M, Bouwes-Bavinck J-N, Naldi L, Viboud C, Roujeau J-C, et al. Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. Aids. 2001;15(14):1843-8.
  152. Roujeau J-C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. Journal of investigative dermatology. 1994;102(6).
  153. Torres‐Navarro I, Briz‐Redon A, Botella‐Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens‐Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2020;34(9):2066-77.
  154. Chateau AV, Dlova NC, Dawood H, Aldous C. Outcomes of Stevens–Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. Southern African journal of HIV medicine. 2019;20(1):1-8.
  155. Lee YY, Ko JH, Wei CH, Chung WH. Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Dermatologica Sinica. 2013 Jun 1;31(2):78-81.
  156. Seminario-Vidal L, Kroshinsky D, Malachowski SJ, Sun J, Markova A, Beachkofsky TM, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. Journal of the American Academy of Dermatology. 2020;82(6):1553-67.

Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce

Information

About ASHMFeedback
Glossary of TermsPrivacy Policy
AcknowledgementsDisclosure Statements

Acknowledgement of Country

We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.

ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM

Scroll to Top